To address whether the Drosophila MLL-AF4 leukemia model would respond to a more relevant novel therapy, we treated the larvae with the MLL-Menin interaction inhibitor VTP50469 that has showed potential in preclinical studies.58 This evidence concerns the gene KMT2A and leukemia.